Discover
JIMD Podcasts
JIMD Podcasts
Author: Journal of Inherited Metabolic Disease
Subscribed: 39Played: 2,509Subscribe
Share
© All rights reserved
Description
JIMD Podcasts is home to the Journal of Inherited Metabolic Disease podcast and the JIMD Shortcast. We're also proud to showcase Metabolic Mysteries and the new Footprints in IMD podcast.
299 Episodes
Reverse
Silvia Radenkovič and Rodrigo Starosta are joined by Curtis Coughlin (University of Colorado, USA) and Guilhian Leipnitz (Universidade Federal do Rio Grande do Sul, Brazil) to discuss Glutaric Aciduria type 1 (GA1), from current care to emerging therapeutic approaches.
Newborn screening and early treatment have substantially improved outcomes, but important questions remain about the mechanisms of brain injury and how best to assess new treatments.
The discussion covers the changing clinical spectrum of GA1, the limitations of biochemical markers in predicting neurological outcomes, and the particular vulnerability of the striatum. Our guests review current management before exploring experimental approaches including GCDH gene replacement, inhibition of lysine degradation through AASS, and the mitochondria-targeted antioxidant JP4-039.
They also consider research into carnitine’s potential anti-inflammatory effects, the limitations of existing animal models, and the challenges of translating laboratory findings into meaningful benefits for patients.
Could a single gene therapy treatment replace lifelong treatment for Gaucher disease?
In this episode of the JIMD Podcast, James speaks with Dr Aneal Khan about the first published case of Gaucher disease treated with lentiviral-mediated gene therapy, with five-year follow-up showing sustained clinical and biochemical improvements without further disease-specific treatment.
They explore the science behind the approach, the remarkable outcomes for this patient, and the challenges of balancing long-term benefits against the risks of treatment. Their conversation also considers the wider future of gene therapy in inherited metabolic diseases, including durability, safety, affordability and access.
Gaucher Disease Treated With Lentiviral-Mediated Gene Therapy: First Case
Mona Shafey, Nicole Prokopishyn and Aneal Khan
https://doi.org/10.1002/jimd.70221
Can hydrotherapy improve quality of life for people with Hunter syndrome (MPS II)?
In this JIMD Reports Shortcast, Andy Oldham, specialist metabolic physiotherapist at Salford Royal Hospital, presents findings from a pilot study exploring the impact of hydrotherapy on pain, mobility and health-related quality of life.
Andy discusses the potential of hydrotherapy to complement enzyme replacement therapy and address some of the everyday challenges of living with MPS II.
The Impact of Hydrotherapy on Health-Related Quality of Life, Pain and Mobility in Individuals With Mucopolysaccharidosis Type II (Hunter Syndrome): A Pilot Feasibility Study
Andrew Oldham, et al
https://doi.org/10.1002/jmd2.70114
On behalf of the MPS Society
An initial diagnosis offered some answers for a child with developmental delay, seizures and progressive spinal curvature. But several features remained unexplained. Dr Karla Cifuentes-Uribe follows an unexpected clue from a routine blood test, revealing why a diagnosis should not always mark the end of the investigation.
Read the paper: https://doi.org/10.1002/jmd2.70117
Where a reaction happens may matter as much as the reaction itself. Manon Jeandel joins James Nurse to discuss evidence that methionine synthase is active in the nucleus and interacts with MATα2 and DNMT3B. We explore the connections between one-carbon metabolism, DNA methylation and cellular compartmentalisation, and the questions these findings raise for inherited metabolic disease.
Methionine Synthase Interacts With the Methionine Adenosyl-Transferase MATα2 and the DNA Methyltransferase DNMT3b in the Nucleus
Manon Jeandel, et al
https://doi.org/10.1002/jimd.70211








